SGLT2 Inhibitors
Sort by:
Frank Lavernia
Diabetes Care in an Underserved Population Clinic
FEATURING
Carrie O'Day
- 1 view
- May 3, 2024
ACC 2024 Insights
ACC 2024 Insights: Evolving Pharmacology for HFrEF vs. HFpFF - With or Without Chronic Kidney Disease and/or Diabetes
FEATURING
Maria Costanzo
- 1,157 views
- April 16, 2024
- 17
ACC 2024 Insights
ACC 2024 Insights: Use of Guidelines in Treatment of Chronic Coronary Disease in Older Adults
FEATURING
John Mulrow
- 943 views
- April 16, 2024
- 7
KDIGO
Primary Care in Chronic Kidney Disease: Insights from the KDIGO 2024 CKD Guideline
FEATURING
Michael Shlipak
- 246 views
- April 8, 2024
- 2
MUSC Cardiology
Where Lie the Keys to Treatment of Type 2 Diabetes Mellitus? Finding the Perfect Fit in Comprehensive Diabetes Treatment
FEATURING
Kathie Hermayer
- 679 views
- March 28, 2024
- 6
MUSC Cardiology
Panel Discussion on Treatments of Type 2 Diabetes and Obesity
- 6 views
- March 28, 2024
MUSC Cardiology
A New Era in Renal Protection in Cardiometabolic Disease
FEATURING
Chakradhari Inampudi
- 210 views
- March 26, 2024
- 2
MUSC Cardiology
Panel Discussion on MASLD Management, SGLT2 inhibitors, Obesity and Sleep Apnea
- 11 views
- March 26, 2024
The Texas Heart Institute
Updates in Guidelines for the Management of Chronic Coronary Artery Disease: What We Should Pay Closer Attention To
FEATURING
Salim Virani
- 838 views
- March 15, 2024
- 10
The Texas Heart Institute
Current Guidelines and Management Strategies in Heart Failure
FEATURING
Biykem Bozkurt
- 1,000 views
- March 14, 2024
- 6
UChicago Medicine
S-QUAD Therapy and Beyond: HFpEF in 2024
FEATURING
Mark Belkin
- 123 views
- March 12, 2024
- 3
Scripps Health
Therapies for Pulmonary Venous Hypertension: Updates on the Treatment of HFpEF
FEATURING
Rajeev Mohan
- 798 views
- February 27, 2024
- 6
Georgia Heart Institute
Comprehensive Care of the Cardiomyopathy Patient: From Pillars that Sustain to Buttresses that Assist
FEATURING
J. Eduardo Rame
- 227 views
- February 8, 2024
- 1
The Texas Heart Institute
New Approaches to HFpEF in the Era of Precision Medicine
FEATURING
Sanjiv J. Shah
- 234 views
- January 22, 2024
- 2
The Texas Heart Institute
Antihyperglycemic Medications for CV Risk Reduction: a Cardiologist's Perspective
FEATURING
Darren K. Mcguire
- 1,226 views
- January 18, 2024
- 10
Houston Methodist Hospital
The Role of MRAs and ERAs in Delaying CKD Progression
FEATURING
Rajiv Agarwal
- 969 views
- December 12, 2023
- 6
Michigan Medicine
How and When To Treat Fatty Liver Disease
FEATURING
Vincent Chen
- 1,420 views
- December 9, 2023
- 7
Houston Methodist Hospital
SGLT2 Inhibitors: Good for the Kidneys, Heart and Vascular System
FEATURING
George Bakris
- 1,357 views
- December 6, 2023
- 7
Primary Care Education Consortium
A Pathophysiologic Approach for Treating Type 2 Diabetes: Part 2
FEATURING
Eden Miller
- 2,253 views
- November 30, 2023
- 20
Primary Care Education Consortium
A Pathophysiologic Approach for Treating Type 2 Diabetes: Part 3
FEATURING
James Gavin Iii
- 644 views
- November 30, 2023
- 10
Keck School of Medicine of USC
Heterogeneity and Therapy Options for T2D: Q&A Discussion
FEATURING
Anne Peters,
Nairi Berner
- 5 views
- November 30, 2023